Iovance Biotherapeutics vs Moolec Science SA
Moolec Science SA is the larger business, with $334m of revenue in fiscal 2025 against $264m for Iovance Biotherapeutics (1.3 times as much). Iovance Biotherapeutics grew faster (60.6% against -28.5%). Moolec Science SA kept more of each dollar of sales as profit: a net margin of -33.4% against -148.4%.
| Latest fiscal year | Iovance BiotherapeuticsIOVA, 2025 | Moolec Science SAMLEC, 2025 |
|---|---|---|
| Revenue | $264m | $334m |
| Revenue growth | 60.6% | -28.5% |
| Net income | −$391m | −$111m |
| Operating margin | — | -31.2% |
| Net margin | -148.4% | -33.4% |
| Return on equity | -55.5% | — |
| Free cash flow | −$336m | −$2.0m |
| Cash | $163m | $767,919 |
| Total debt | — | $1.3m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 975 | — |
| Market value | $3.95bn | $9.3m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |